efficacy

2:53
Effect of FGFR status on checkpoint inhibitor response in bladder cancer
Tracy Rose
4:10
Non-clear cell kidney cancer trial updates: CALYPSO and KEYNOTE-427
Tracy Rose
2:46
IO-IO vs. IO-VEGF inhibitor therapy for mRCC
Shaan Dudani
1:26
SPIRE trial: overcoming cisplatin resistance in bladder cancer with transcriptome changes
Simon Crabb
1:46
New promise in treating mBC: combining anti-AR therapy with chemotherapy
Shilpa Gupta
2:20
ProCAID: Investigating the use of AZD5363 alongside chemotherapy in mCRPC
Simon Crabb
2:40
Key prostate cancer news from GU 2019
Simon Crabb
4:13
Using the urinary microbiome to predict BCG therapy responses in bladder cancer patients.
Randy Sweis
5:30
Zuclomiphene citrate: overcoming the estrogenic side effects of ADT in mCRPC patients
Robert Getzenberg
4:10
Combination of minimally invasive surgery and carboplatin for stage IIa seminoma
Robert Huddart
2:05
Immunotherapy resistance mechanisms and predicting NMIBC patient immune responses.
Randy Sweis
2:29
Bladder cancer treatment updates by Prof. Jones
Robert Jones
1:25
Progress and challenges of immunotherapy for bladder cancer
Randy Sweis
2:07
Key updates on testicular cancer management
Robert Huddart
1:44
Renal cancer highlights from 2019 GU: KEYNOTE-426
Robert Jones
1:02
Non-clear cell sarcamatoid kidney cancer treatment updates
Rana McKay
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals